Zydus Lifesciences Ltd. on Tuesday announced its unaudited consolidated financial results for the quarter and half year ended September 30th, 2024. The company’s net profit for the July to September period surged 13.7% year-on-year to Rs. 911 crore, compared to Rs. 801 crore reported in the same quarter last year.
Zydus Lifesciences spent Rs 480 crore in R&D for the quarter ending September, 2024 which is 9.2 percent of its revenues.
Meanwhile, EBITDA rose 27.5 percent on-year to Rs.1,461.4 crore. The same was Rs. 1,146 crore in the corresponding period of last year. According to the company’s statement, Capex (organic) for the quarter was Rs. 3,01.7 crore.
“Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and
strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions, keeping patient centricity at the core,” Dr. Sharvil Patel, Managing Director – Zydus Lifesciences Limited said.
According the company’s statement, the company’s Consumer business registered revenues of Rs. 4,87.5 crore, up 12 % y-o-y. The growth was primarily led by 8.4% volume growth. The business accounted for 10% of revenues.
Both the personal care segment and food & nutrition segment performed well, driving the overall performance of the business.
Recently, in the month of October, 2024, entered into a definitive agreement to acquire Naturell (India) Pvt. Ltd, a leading healthy snacking company. It is engaged in the business of manufacturing, R&D, marketing and selling of Nutrition bars, Protein cookies, Protein Chips and health food products under brands Ritebite Max Protein and Ritebite.